Revolution Medicines (RVMD) Stock Forecast & Price Target

Compare

530 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RVMD Analyst Ratings

Strong Buy

18 Buy

0 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Revolution

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$79.76

▲(29.94% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $79.76 with a high forecast of $104.00 and a low forecast of $67.00. The average price target represents a 29.94% change from the last price of $61.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","105":"$105","50.25":"$50.3","68.5":"$68.5","86.75":"$86.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$79.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.25,68.5,86.75,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.84,62.31384615384616,65.78769230769231,69.26153846153846,72.73538461538462,76.20923076923077,79.68307692307692,83.15692307692308,86.63076923076923,90.10461538461539,93.57846153846154,97.05230769230769,100.52615384615385,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.84,60.44923076923077,62.05846153846154,63.66769230769231,65.27692307692308,66.88615384615385,68.49538461538462,70.10461538461539,71.71384615384616,73.32307692307693,74.9323076923077,76.54153846153847,78.15076923076924,{"y":79.76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.84,59.46769230769231,60.09538461538462,60.723076923076924,61.35076923076923,61.97846153846154,62.606153846153845,63.23384615384616,63.861538461538466,64.48923076923077,65.11692307692307,65.74461538461539,66.37230769230769,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$104.00

Average Price Target$79.76

Lowest Price Target$67.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

$77

Buy

25.45%

Upside

Reiterated

11/06/25

Ami Fadia

Needham

$66→$72

Buy

17.30%

Upside

Reiterated

11/06/25

Revolution Medicines: Buy Rating Reaffirmed Amid Strategic Developments and Increased Price TargetWe update our model for the quarter and increase the ramp for daraxonrasib in PDAC which increases our PT to $72. Reiterate Buy.

Alec Stranahan

Bank of America Securities

$80→$82

Buy

33.59%

Upside

Reiterated

11/06/25

Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)We reiterate Buy and $82 PO (from $80) with RevMed remaining one of our top picks.

Laura Prendergast

Stifel Nicolaus

$85

Buy

38.48%

Upside

Reiterated

11/06/25

Stifel Nicolaus Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Robert Burns

H.C. Wainwright

$72→$73

Buy

18.93%

Upside

Reiterated

11/06/25

Revolution Medicines price target raised to $73 from $72 at H.C. WainwrightRevolution Medicines price target raised to $73 from $72 at H.C. Wainwright

Brian Cheng

J.P. Morgan

$71→$82

Buy

33.59%

Upside

Reiterated

11/06/25

JPMorgan ups Revolution Medicines target, adds to Analyst Focus ListJPMorgan ups Revolution Medicines target, adds to Analyst Focus List

Asthika Goonewardene

Truist Financial

$99

Buy

61.29%

Upside

Reiterated

11/06/25

Truist Financial Keeps Their Buy Rating on Revolution Medicines (RVMD)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$90

Buy

46.63%

Upside

Reiterated

11/06/25

Mizuho Securities Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/05/25

Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy RatingWe continue to believe RVMD is establishing a new SOC across lines of PDAC that alone can provide upside. POC is also being established across multiple additional agents/indications. Remain Buy.

Charles Zhu

LifeSci Capital

$80→$104

Buy

69.44%

Upside

Reiterated

11/05/25

Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements

Jay Olson

Oppenheimer

$75

Buy

22.19%

Upside

Reiterated

10/27/25

Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Peter Lawson

Barclays

$72

Buy

17.30%

Upside

Reiterated

10/23/25

Revolution Medicines (RVMD) Receives a Buy from Barclays

Jonathan Chang

Leerink Partners

$64→$67

Buy

9.16%

Upside

Reiterated

10/20/25

Revolution Medicines (RVMD) Gets a Buy from Leerink Partners

Michael Schmidt

Guggenheim

$80

Buy

30.34%

Upside

Reiterated

10/19/25

Revolution Medicines (RVMD) Gets a Buy from GuggenheimWe reiterate our Buy rating in RVMD based on our bullish view on the daraxonrasib opportunity.

Kelsey Goodwin

Piper Sandler

$75

Buy

22.19%

Upside

Reiterated

10/17/25

Revolution Medicines (RVMD) Receives a Buy from Piper SandlerMgmt Call Post-Announcement that RVMD Was Awarded CNPV for Daraxonrasib in PDAC – Reiterating Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

$77

Buy

25.45%

Upside

Reiterated

11/06/25

Ami Fadia

Needham

$66→$72

Buy

17.30%

Upside

Reiterated

11/06/25

Alec Stranahan

Bank of America Securities

$80→$82

Buy

33.59%

Upside

Reiterated

11/06/25

Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)We reiterate Buy and $82 PO (from $80) with RevMed remaining one of our top picks.

Laura Prendergast

Stifel Nicolaus

$85

Buy

38.48%

Upside

Reiterated

11/06/25

Stifel Nicolaus Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Robert Burns

H.C. Wainwright

$72→$73

Buy

18.93%

Upside

Reiterated

11/06/25

Revolution Medicines price target raised to $73 from $72 at H.C. WainwrightRevolution Medicines price target raised to $73 from $72 at H.C. Wainwright

Brian Cheng

J.P. Morgan

$71→$82

Buy

33.59%

Upside

Reiterated

11/06/25

JPMorgan ups Revolution Medicines target, adds to Analyst Focus ListJPMorgan ups Revolution Medicines target, adds to Analyst Focus List

Asthika Goonewardene

Truist Financial

$99

Buy

61.29%

Upside

Reiterated

11/06/25

Truist Financial Keeps Their Buy Rating on Revolution Medicines (RVMD)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$90

Buy

46.63%

Upside

Reiterated

11/06/25

Mizuho Securities Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/05/25

Charles Zhu

LifeSci Capital

$80→$104

Buy

69.44%

Upside

Reiterated

11/05/25

Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements

Jay Olson

Oppenheimer

$75

Buy

22.19%

Upside

Reiterated

10/27/25

Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Peter Lawson

Barclays

$72

Buy

17.30%

Upside

Reiterated

10/23/25

Revolution Medicines (RVMD) Receives a Buy from Barclays

Jonathan Chang

Leerink Partners

$64→$67

Buy

9.16%

Upside

Reiterated

10/20/25

Revolution Medicines (RVMD) Gets a Buy from Leerink Partners

Michael Schmidt

Guggenheim

$80

Buy

30.34%

Upside

Reiterated

10/19/25

Revolution Medicines (RVMD) Gets a Buy from GuggenheimWe reiterate our Buy rating in RVMD based on our bullish view on the daraxonrasib opportunity.

Kelsey Goodwin

Piper Sandler

$75

Buy

22.19%

Upside

Reiterated

10/17/25

Revolution Medicines (RVMD) Receives a Buy from Piper SandlerMgmt Call Post-Announcement that RVMD Was Awarded CNPV for Daraxonrasib in PDAC – Reiterating Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

1 Month

xxx

Success Rate

6/10 ratings generated profit

Average Return

+11.14%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +11.14% per trade.

3 Months

xxx

Success Rate

11/15 ratings generated profit

Average Return

+14.57%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +14.57% per trade.

1 Year

Michael SchmidtGuggenheim

Success Rate

10/10 ratings generated profit

Average Return

+28.43%

reiterated a buy rating 20 days ago

Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.43% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+74.88%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +74.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RVMD has received 42 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 79.76.

Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$1.58 with a range of -$1.70 to -$1.38. The previous quarter’s EPS was -$1.61. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $3.08M with a range of $0.00 to $41.70M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Revolution Medicines’s 12-month average price target is 79.76.

What is RVMD’s upside potential, based on the analysts’ average price target?

Revolution Medicines has 29.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RVMD a Buy, Sell or Hold?

Revolution Medicines has a consensus rating of Strong Buy which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.

What is Revolution Medicines’s price target?

The average price target for Revolution Medicines is 79.76. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $104.00 ,the lowest forecast is $67.00. The average price target represents 29.94% Increase from the current price of $61.38.

What do analysts say about Revolution Medicines?

Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of RVMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Revolution Medicines (RVMD) Stock Forecast & Price Target

RVMD Analyst Ratings

RVMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revolution Medicines

RVMD Analyst Recommendation Trends

RVMD Financial Forecast

RVMD Earnings Forecast

RVMD Sales Forecast

RVMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts